The theme of the current examination was to evaluate the anticancer activity of baicalein (5,6,7-trihydroxyflavone) in human oral cancer KB-cells by observing cell restraint intercellular ROS movement and apoptotic changes using 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide (MTT) assay and 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) test. The concentration of baicalein at 80 μM caused 100% cancer cell inhibition. Therefore, lower concentrations i.e. 10, 20 and 40 μM were selected in the present study. Baicalein at 40 μM significantly hindered human oral cancer KB cells. In the interim, incendiary and apoptosis were seen through expanded ROS action that actuated apoptotic cell death. The results of the present study suggested that the anticancer effect of baicalein is likely due to its potential to improve ROS level and hence the increased apoptotic activity. This study suggested that baicalein might be a potential candidate for the treatment of oral cancer.